Xu et al. reported that targeting SLC7A11, a cystine/glutamate antiporter, is a potential strategy in the treatment of CRC; erastin inhibited SLC7A11 and selectively killed CRC stem cells by inducing ferroptosis and attenuating chemoresistance in CRC [12]. Here, SLC7A11 is linked to colorectal carcinoma.